Erudio Healtherudio.com
Sponsor
Dizal Pharmaceuticals trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Dizal Pharmaceuticals yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by Dizal Pharmaceuticals: TIAN-SHAN1, WU-KONG1, WU-KONG6 and WU-KONG28. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Dizal Pharmaceuticals). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| WU-KONG28 NCT05668988 · Dizal Pharmaceuticals DeepView → | first-line EGFR exon 20 insertion-mutated advanced NSCLC | Phase 3 | Deep | View | |||
| WU-KONG1 NCT03974022 · Dizal Pharmaceuticals DeepView → | advanced NSCLC with EGFR or HER2 mutation | Phase 1/Phase 2 | Deep | View | |||
| WU-KONG6 NCT05712902 · Dizal Pharmaceuticals StandardView → | platinum-pretreated EGFR exon 20 insertion advanced NSCLC | Phase 2 | Standard | View | |||
| TIAN-SHAN1 NCT06905197 · Dizal Pharmaceuticals FocusedView → | advanced NSCLC with EGFR mutations | Phase 1 | Focused | View | |||